Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/348479
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampBértolo, Manoel Barros-
dc.typeArtigopt_BR
dc.titleInvestigation on brazilian clinical practices in rheumatoid arthritis :the brazilian rheumatoid arthritis clinical practices investigation-BRACTICEpt_BR
dc.contributor.authorHelfenstein, Milton-
dc.contributor.authorHalpern, Ari Stiel Radu-
dc.contributor.authorBertolo, Manoel Barros-
dc.subjectArtrite reumatóidept_BR
dc.subject.otherlanguageArthritis, rheumatoidpt_BR
dc.description.abstractRheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease causing significant social, medical, and economic impact. Several therapeutic regimens are available within the medical arsenal. The rational and reasoned use of various medications approved for their treatment is imperative. This study aimed to evaluate how Brazilian rheumatologists use the drugs available to combat the disease. For this, 128 Brazilian rheumatologists from public and private health services responded to an 18-item questionnaire, sent over the Internet, about different situations of drug treatment of RA. The answers helped to confirm the trends among Brazilian rheumatologists in the drug treatment of RA. The study results have shown that most Brazilian rheumatologists follow the guidelines and consensus established by the Brazilian Society of Rheumatology for the treatment of RA. A small proportion, however, start the biologic therapy in early stages of the disease, including the very early stage, as the first treatment option. Most experts use corticosteroids in low doses early in the treatment. This study confirms that the majority but not all Brazilian rheumatologists follow, in their daily practice, established guidelines and consensus for the treatment of RA. However, it also shows that some few rheumatologists start with anti-tumor necrosis factor therapy in very early arthritis independently of disease severity or prognostic factorspt_BR
dc.relation.ispartofJournal of clinical rheumatologypt_BR
dc.relation.ispartofabbreviationJ. clin. rheumatol.pt_BR
dc.publisher.cityPhiladelphia, PApt_BR
dc.publisher.countryEstados Unidospt_BR
dc.publisherLippincott Williams & Wilkinspt_BR
dc.date.issued2011-
dc.date.monthofcirculationJunept_BR
dc.language.isoengpt_BR
dc.description.volume17pt_BR
dc.description.issuenumber4pt_BR
dc.description.issuesupplement1pt_BR
dc.description.firstpageS1pt_BR
dc.description.lastpageS10pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn1076-1608pt_BR
dc.identifier.eissn1536-7355pt_BR
dc.identifier.doi10.1097/RHU.0b013e3182224ea4pt_BR
dc.identifier.urlhttps://journals.lww.com/jclinrheum/Fulltext/2011/06000/Investigation_on_Brazilian_Clinical_Practices_in.21pt_BR
dc.date.available2020-09-01T17:57:45Z-
dc.date.accessioned2020-09-01T17:57:45Z-
dc.description.provenanceSubmitted by Mariana Aparecida Azevedo (mary1@unicamp.br) on 2020-09-01T17:57:45Z No. of bitstreams: 0. Added 1 bitstream(s) on 2021-01-04T15:14:53Z : No. of bitstreams: 1 000291383400001.pdf: 1797964 bytes, checksum: 69f51dbf6983c15111e13664891e9f3b (MD5)en
dc.description.provenanceMade available in DSpace on 2020-09-01T17:57:45Z (GMT). No. of bitstreams: 0 Previous issue date: 2011en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/348479-
dc.contributor.departmentDepartamento de Clínica Médicapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordDrug treatmentpt_BR
dc.subject.keywordConsensuspt_BR
dc.subject.keywordGuidelinespt_BR
dc.identifier.source000291383400001pt_BR
dc.creator.orcidsem informaçãopt_BR
dc.type.formArtigopt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000291383400001.pdf1.76 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.